Meeting Coverage
ACTRIMS
Americas Committee for Treatment and Research in Multiple Sclerosis
Latest ACTRIMS Meeting Coverage
No efficacy difference between the two drugs in two phase III trials
Processing speed scores lower 4 years later for people with one or more baseline lesions
Clinical, radiologic measures remained stable or improved in both younger and older patients
Tough to pinpoint what is a long-term MS symptom and what is a long COVID symptom
Increased risk of physical, psychological, cognitive decline
Real-world data analysis compares oral disease-modifying therapies
No new relapses recorded after autologous transplant
Predictive enrichment could increase the power of future trials
Sensitivity, accuracy also high in prospective study
Ventricular enlargement was second strongest indicator
Subset of multiple sclerosis patients seroconverted after third dose, however
Urinary, kidney infections especially are more common for people with MS than others
The issue: some multiple sclerosis drugs may attenuate antibody responses to vaccination
North American data echoes findings from around the world
Latest Neurology Meeting Coverage
-
AANEM: American Association of Neuromuscular & Electrodiagnostic Medicine
October 2024
-
ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
September 2024
-
AAN: American Academy of Neurology
April 2024
-
ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis
March 2024